Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Meiragtx Holdings Plc
(NQ:
MGTX
)
4.170
+0.040 (+0.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Meiragtx Holdings Plc
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
August 12, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
August 12, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
May 09, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
April 24, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
April 18, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
March 14, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
February 13, 2024
MeiraGTx to receive $50 million milestone after initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of...
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
December 21, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
November 21, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
November 14, 2023
From
MeiraGTx
Via
GlobeNewswire
BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions
October 31, 2023
Best Growth Stocks, a leading independent research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a...
Via
TheNewswire.com
MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities
October 30, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
October 24, 2023
Multiple Posters and Oral Presentations Highlight the Depth of Innovation from MeiraGTx’s Technology Platforms for Gene and Cell Therapy
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports Second Quarter 2023 Financial and Operational Results
August 10, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
August 01, 2023
RiboCAR-T cell activity can be precisely tuned and “remotely” controlled to improve the efficacy, durability and safety of CAR-T cell therapy
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing
July 19, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
June 27, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,
June 22, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting
May 16, 2023
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports First Quarter 2023 Financial and Operational Results
May 11, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces $60 Million Private Placement of Ordinary Shares
May 03, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
April 21, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
April 20, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
March 14, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
December 13, 2022
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
December 08, 2022
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
November 22, 2022
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.
November 10, 2022
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress
October 04, 2022
Multiple Poster Presentations Highlight Versatility and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy
From
MeiraGTx
Via
GlobeNewswire
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)
October 01, 2022
Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial of botaretigene sparoparvovec in XLRP, which...
From
MeiraGTx
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.